Abstract

Background: The present study was a multicenter, retrospective study which aimed to evaluate the efficacy of propofol, a new choice of pharmacotherapy in head-injured patients. Methods: Head-injured patients admitted to 3 hospitals during the period from January 2003 to December 2004 were included in this clinical trial. Data on patients' demographics, laboratory data, GCS score, ICP, CPP, concurrent medications, and therapeutic outcomes were collected. Results: Among the 104 patients included, only 44 were given propofol. The average age was 40.8 ± 22 years for all patients, with 41.91 ± 20.41 and 43.48 ± 23.19 years for the propofol group and nonpropofol group, respectively (P = .097). There was no significant difference in baseline GCS score between the 2 groups (5.86 ± 1.84 vs 5.66 ± 1.59, P = .729). Mean ICP for the first 3 days in the ICU was 17.23 ± 9.0 mm Hg in the propofol group and 33.19 ± 32.56 in the nonpropofol group, respectively (P = .017). Mean CPP for the first 5 days in the ICU was 71.10 ± 15.32 mm Hg in the propofol group and 43.20 ± 29.92 mm Hg in the nonpropofol group (P <.001). A higher survival rate was found in the propofol group (81.8% vs 46.7%, P <.001). Conclusions: The present study demonstrated that propofol improved the outcome in recovery phase of head-injured patients.

Original languageEnglish
JournalSurgical Neurology
Volume66
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Propofol
Taiwan
Head
Multicenter Studies
Survival Rate
Retrospective Studies
Demography
Clinical Trials
Drug Therapy

Keywords

  • Head injury
  • Head trauma
  • Intracranial pressure
  • Propofol
  • Sedatives

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Multicenter evaluation of propofol for head-injured patients in Taiwan. / Chiu, Wen Ta; Lin, Tien Jen; Lin, Jia Wei; Huang, Sheng Jean; Chang, Cheng Kuei; Chen, Hsiang Yin.

In: Surgical Neurology, Vol. 66, No. SUPPL. 2, 11.2006.

Research output: Contribution to journalArticle

@article{d5ba9f243cbc4fab847bcb78ea6356a9,
title = "Multicenter evaluation of propofol for head-injured patients in Taiwan",
abstract = "Background: The present study was a multicenter, retrospective study which aimed to evaluate the efficacy of propofol, a new choice of pharmacotherapy in head-injured patients. Methods: Head-injured patients admitted to 3 hospitals during the period from January 2003 to December 2004 were included in this clinical trial. Data on patients' demographics, laboratory data, GCS score, ICP, CPP, concurrent medications, and therapeutic outcomes were collected. Results: Among the 104 patients included, only 44 were given propofol. The average age was 40.8 ± 22 years for all patients, with 41.91 ± 20.41 and 43.48 ± 23.19 years for the propofol group and nonpropofol group, respectively (P = .097). There was no significant difference in baseline GCS score between the 2 groups (5.86 ± 1.84 vs 5.66 ± 1.59, P = .729). Mean ICP for the first 3 days in the ICU was 17.23 ± 9.0 mm Hg in the propofol group and 33.19 ± 32.56 in the nonpropofol group, respectively (P = .017). Mean CPP for the first 5 days in the ICU was 71.10 ± 15.32 mm Hg in the propofol group and 43.20 ± 29.92 mm Hg in the nonpropofol group (P <.001). A higher survival rate was found in the propofol group (81.8{\%} vs 46.7{\%}, P <.001). Conclusions: The present study demonstrated that propofol improved the outcome in recovery phase of head-injured patients.",
keywords = "Head injury, Head trauma, Intracranial pressure, Propofol, Sedatives",
author = "Chiu, {Wen Ta} and Lin, {Tien Jen} and Lin, {Jia Wei} and Huang, {Sheng Jean} and Chang, {Cheng Kuei} and Chen, {Hsiang Yin}",
year = "2006",
month = "11",
doi = "10.1016/j.surneu.2006.08.028",
language = "English",
volume = "66",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Multicenter evaluation of propofol for head-injured patients in Taiwan

AU - Chiu, Wen Ta

AU - Lin, Tien Jen

AU - Lin, Jia Wei

AU - Huang, Sheng Jean

AU - Chang, Cheng Kuei

AU - Chen, Hsiang Yin

PY - 2006/11

Y1 - 2006/11

N2 - Background: The present study was a multicenter, retrospective study which aimed to evaluate the efficacy of propofol, a new choice of pharmacotherapy in head-injured patients. Methods: Head-injured patients admitted to 3 hospitals during the period from January 2003 to December 2004 were included in this clinical trial. Data on patients' demographics, laboratory data, GCS score, ICP, CPP, concurrent medications, and therapeutic outcomes were collected. Results: Among the 104 patients included, only 44 were given propofol. The average age was 40.8 ± 22 years for all patients, with 41.91 ± 20.41 and 43.48 ± 23.19 years for the propofol group and nonpropofol group, respectively (P = .097). There was no significant difference in baseline GCS score between the 2 groups (5.86 ± 1.84 vs 5.66 ± 1.59, P = .729). Mean ICP for the first 3 days in the ICU was 17.23 ± 9.0 mm Hg in the propofol group and 33.19 ± 32.56 in the nonpropofol group, respectively (P = .017). Mean CPP for the first 5 days in the ICU was 71.10 ± 15.32 mm Hg in the propofol group and 43.20 ± 29.92 mm Hg in the nonpropofol group (P <.001). A higher survival rate was found in the propofol group (81.8% vs 46.7%, P <.001). Conclusions: The present study demonstrated that propofol improved the outcome in recovery phase of head-injured patients.

AB - Background: The present study was a multicenter, retrospective study which aimed to evaluate the efficacy of propofol, a new choice of pharmacotherapy in head-injured patients. Methods: Head-injured patients admitted to 3 hospitals during the period from January 2003 to December 2004 were included in this clinical trial. Data on patients' demographics, laboratory data, GCS score, ICP, CPP, concurrent medications, and therapeutic outcomes were collected. Results: Among the 104 patients included, only 44 were given propofol. The average age was 40.8 ± 22 years for all patients, with 41.91 ± 20.41 and 43.48 ± 23.19 years for the propofol group and nonpropofol group, respectively (P = .097). There was no significant difference in baseline GCS score between the 2 groups (5.86 ± 1.84 vs 5.66 ± 1.59, P = .729). Mean ICP for the first 3 days in the ICU was 17.23 ± 9.0 mm Hg in the propofol group and 33.19 ± 32.56 in the nonpropofol group, respectively (P = .017). Mean CPP for the first 5 days in the ICU was 71.10 ± 15.32 mm Hg in the propofol group and 43.20 ± 29.92 mm Hg in the nonpropofol group (P <.001). A higher survival rate was found in the propofol group (81.8% vs 46.7%, P <.001). Conclusions: The present study demonstrated that propofol improved the outcome in recovery phase of head-injured patients.

KW - Head injury

KW - Head trauma

KW - Intracranial pressure

KW - Propofol

KW - Sedatives

UR - http://www.scopus.com/inward/record.url?scp=33750320425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750320425&partnerID=8YFLogxK

U2 - 10.1016/j.surneu.2006.08.028

DO - 10.1016/j.surneu.2006.08.028

M3 - Article

C2 - 17071254

AN - SCOPUS:33750320425

VL - 66

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

IS - SUPPL. 2

ER -